CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.77 USD | -1.60% |
|
-7.40% | +15.84% |
| Feb. 09 | HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating | MT |
| Feb. 08 | Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 8.35M | Sales 2025 * | 8.74M | Capitalization | 87.06M |
|---|---|---|---|---|---|
| Net income 2024 * | -49M | Net income 2025 * | -55M | EV / Sales 2024 * | 10.4 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.97 x |
| P/E ratio 2024 * |
-2.44
x | P/E ratio 2025 * |
-2.72
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -1.60% | ||
| 1 week | -7.40% | ||
| Current month | +35.88% | ||
| 1 month | +36.76% | ||
| 3 months | +62.31% | ||
| 6 months | +277.75% | ||
| Current year | +15.84% |
1 week
14.06
15.16
1 month
10.0217.49
Current year
8.2417.49
1 year
3.8019.60
3 years
3.80348.00
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
| Chief Tech/Sci/R&D Officer | - | 22-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 03-10-31 | |
| Chairman | 82 | 00-02-13 | |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 14.77 | -1.60% | 4,734 |
| 24-04-23 | 15.01 | +1.08% | 5,785 |
| 24-04-22 | 14.85 | +3.77% | 21,156 |
| 24-04-19 | 14.31 | -5.98% | 10,228 |
| 24-04-18 | 15.22 | -4.58% | 19,676 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.77
USD
Average target price
93
USD
Spread / Average Target
+529.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.84% | 87.06M | |
| +4.09% | 43.84B | |
| +46.96% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- CRIS Stock
